‘Global Bio-Mems & Microfluidics Market Worth Over $2.8 Billion In 2017’ Says Visiongain Report

14 August 2017
Pharma

Visiongain’s new report World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography indicates that the global Bio-MEMS & Microfluidics market will see over $2.8bn in revenue in 2017.
The lead analyst of the report said:

“Micro-electro mechanical systems (MEMS) refers to the technology of microscopic devices, in particular, those with mechanical parts. Bio-MEMS therefor refer to the microscopic devices and microfabrication technologies which are suitable for biological applications. Microfluidics instead deals with the operation, performance and exact control of fluids which are constrained to a small (sub-millimeter) scale. These systems are broadly used for biological and biomedical purposes. In addition, bio-MEMS are also used for clinical diagnostics and research and development in the healthcare sector for numerous applications. For instance, the introduction of accelerometers in pacemakers have revolutionized the treatment of cardiac diseases. Further, using bio-MEMS devices there is a possibility of improving the delivery of transdermal drugs, which are currently limited to passive diffusion devices.

Rising demand to treat critically ill patients and use of artificial limbs and the treatment nerve problems have been a major factor for the growth of bio MEMS market. Uptake of microfluidics in a wide range of biomedical applications for diagnostic and analytical purposes as well as enhanced detection of pathogens and viruses using bio-MEMS are other major factors influencing the growth of this market. In addition, complex manufacturing procedures for MEMS and sophisticated fabrication techniques has been a core restraint for the growth of this market. Furthermore, the expensive nature of this technology and its reliance on a technologically advanced medical infrastructure has made adoption of bio-MEMS comparatively more difficult. Hence, some governments are introducing new reimbursement programs and increasing healthcare infrastructure to allow for these new technologies to become more widely adopted. This is creating more lucrative opportunities for top players to invest in emerging economies such as China and India.

The global bio-MEMS and microfluids market is segmented based on type, application and end user. Based on type the market is classified into implantable bio-MEMS, injectable bio-MEMS, and other devices. Further, based on application the market is classified into diagnostics, therapeutics, tissue engineering and others. Furthermore, based on end user it is segmented for the pharmaceutical industry, hospitals, research centres and others. ”

The 206-page report contains 204 tables, charts and graphs that add visual analysis in order to explain developing trends within the Bio-MEMS & Microfluidics market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Bio-MEMS & Microfluidics software submarkets, segmented by type, including forecasts for Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters and Micro Motors. The market is also segmented by application, with forecasts for Diagnostic, Therapeutic and Tissue Engineering from 2017-2027. In addition, the Bio-MEMS & Microfluidics market is segmented by end-user, with forecasts for Pharmaceutical Industry, Hospitals, Research Centres.

The 206-page report offers market forecasts and analysis for 7 key regional and 17 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Bio-MEMS & Microfluidics field in detail.

The World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography report will be of value to anyone who wants to better understand the Bio-MEMS & Microfluidics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Bio-MEMS & Microfluidics industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever